Vedanta Biosciences Appoints Susan Dillon, PhD, to Board of Directors Vedanta Biosciences Appoints Susan Dillon, PhD, to Board of Directors
Former Global Head of Immunology at Janssen led development of multiple innovative therapies Vedanta Biosciences, a clinical stage company developing a... Vedanta Biosciences Appoints Susan Dillon, PhD, to Board of Directors

Former Global Head of Immunology at Janssen led development of multiple innovative therapies

Vedanta Biosciences, a clinical stage company developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced the appointment of industry leader Susan Dillon, Ph.D., as an independent member of its Board of Directors. Dr. Dillon brings a wealth of drug development experience in immunology and infectious disease, having led the approvals and expansions of several blockbuster products.

Chris Viehbacher, Chairman of Vedanta Biosciences’ Board of Directors and Managing Partner of Gurnet Point Capital said, “Dr. Dillon is a recognized leader in the field of immunology who brings an impressive track record from her tenure at Janssen Research & Development. We are delighted to welcome her to the Vedanta Biosciences Board and look forward to her insights as we continue to pioneer the microbiome field.”

Dr. Dillon said, “I have followed the microbiome field closely and believe Vedanta Biosciences is building the industry’s leading platform with compelling science, impressive R&D, and manufacturing capabilities. I am excited to be joining the Board of Directors and I look forward to working with this exceptional team.”

Dr. Dillon is Co-founder, President, and Chief Executive Officer of Aro Biotherapeutics, a biotechnology company focused on next generation protein medicines. Prior to Aro Biotherapeutics, Dr. Dillon served as Global Therapeutic Area Head for Immunology at Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. During her 16-year tenure, Dr. Dillon led biologics discovery and global Immunology R&D teams that were responsible for achieving numerous regulatory approvals for innovative antibody products for autoimmune diseases that delivered combined sales in excess of $10 billion, including REMICADE®, SIMPONI®, STELARA®, and most recently TREMFYA®, the first anti-IL-23 monoclonal antibody to be approved.

Dr. Dillon currently serves on the Board of Directors of the Wistar Institute and is an advisor to the DMAX Foundation which is focused on mental health. In 2013, she was named one of the “Top Women in Biotech” by FierceBiotech. Dr. Dillon earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University, and she holds a B.S. and an M.S. in Medical Technology from State University of New York at Buffalo and Temple University School of Medicine, respectively.

“We are very pleased to have Sue join our Board of Directors,” said Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences. “Sue’s experience leading the development of important immunology-focused medicines from discovery-phase to commercialization will be invaluable as we advance our pipeline. Sue was one of the earliest microbiome champions in the pharmaceutical industry and understands the potential of this field to change medicine.”

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *

analytics.js